OBJECTIVES: Cysteamine prevents organ damage in children with cystinosis, but may cause gastrointestinal (GI) symptoms. In this study we evaluated the nature of GI disease, and the value of omeprazole in controlling GI symptoms in these children. STUDY DESIGN: Upper GI disease was evaluated with endoscopy, gastrin levels, and acid secretion studies after oral administration of cysteamine, before and after 16 weeks of therapy with omeprazole. A symptom score was devised. RESULTS: Eleven children (mean age, 5.7 years) were studied. After cysteamine ingestion, before and after omeprazole therapy, the mean maximum acid output was significantly higher than the mean basal acid output. The maximum acid output was measured within 60 minutes of cysteamine ingestion and was reduced by omeprazole therapy (P<.01). The mean peak gastrin level was 30 minutes postcysteamine and was higher than baseline (P<.01). The initial mean symptom score (maximum score, 14) was 6.9 and fell to 0.7 (P<.0001) after 16 weeks of omeprazole therapy. At endoscopy, two children had diffuse gastric nodularity, and nearly all had cystine crystal deposits. CONCLUSIONS: GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole. Cystine crystals were detected in the GI tract and may signify inadequate treatment with cysteamine.
OBJECTIVES:Cysteamine prevents organ damage in children with cystinosis, but may cause gastrointestinal (GI) symptoms. In this study we evaluated the nature of GI disease, and the value of omeprazole in controlling GI symptoms in these children. STUDY DESIGN: Upper GI disease was evaluated with endoscopy, gastrin levels, and acid secretion studies after oral administration of cysteamine, before and after 16 weeks of therapy with omeprazole. A symptom score was devised. RESULTS: Eleven children (mean age, 5.7 years) were studied. After cysteamine ingestion, before and after omeprazole therapy, the mean maximum acid output was significantly higher than the mean basal acid output. The maximum acid output was measured within 60 minutes of cysteamine ingestion and was reduced by omeprazole therapy (P<.01). The mean peak gastrin level was 30 minutes postcysteamine and was higher than baseline (P<.01). The initial mean symptom score (maximum score, 14) was 6.9 and fell to 0.7 (P<.0001) after 16 weeks of omeprazole therapy. At endoscopy, two children had diffuse gastric nodularity, and nearly all had cystine crystal deposits. CONCLUSIONS: GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole. Cystine crystals were detected in the GI tract and may signify inadequate treatment with cysteamine.
Authors: Meredith C Fidler; Bruce A Barshop; Jon A Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider; Ranjan Dohil Journal: Br J Clin Pharmacol Date: 2007-01 Impact factor: 4.335
Authors: Elena N Levtchenko; Carin M van Dael; Addy C de Graaf-Hess; Martijn J G Wilmer; Lambertus P van den Heuvel; Leo A Monnens; Henk J Blom Journal: Pediatr Nephrol Date: 2005-10-27 Impact factor: 3.714
Authors: Karlijn J Van Stralen; Francesco Emma; Kitty J Jager; Enrico Verrina; Franz Schaefer; Guido F Laube; Malcolm A Lewis; Elena N Levtchenko Journal: Clin J Am Soc Nephrol Date: 2011-08-25 Impact factor: 8.237
Authors: Craig B Langman; Larry A Greenbaum; Minnie Sarwal; Paul Grimm; Patrick Niaudet; Georges Deschênes; Elisabeth Cornelissen; Denis Morin; Pierre Cochat; Debora Matossian; Segolene Gaillard; Mary Jo Bagger; Patrice Rioux Journal: Clin J Am Soc Nephrol Date: 2012-05-03 Impact factor: 8.237
Authors: Jon A Gangoiti; Meredith Fidler; Betty L Cabrera; Jerry A Schneider; Bruce A Barshop; Ranjan Dohil Journal: Br J Clin Pharmacol Date: 2010-09 Impact factor: 4.335
Authors: M Besouw; L van den Heuvel; R van Eijsden; I Bongaers; L Kluijtmans; M Dewerchin; E Levtchenko Journal: J Inherit Metab Dis Date: 2013-01-31 Impact factor: 4.982